





Paras Biopharmaceuticals
Finland Oy

Your Domain Antibody CDMO

Helping you solve the protein
production puzzle



**Your Partner of choice for
Microbial Manufacturing**

Paras Biopharmaceuticals Finland Oy
June 2023

- ✓ IL-fusion proteins
- ✓ Long Peptides
- ✓ Nanobodies
- ✓ Diabodies
- ✓ Peptibodies
- ✓ Domain antibodies
- ✓ scFvs

INDEX

- ✓ **About Paras Biopharmaceuticals**
- ✓ **Microbial Technologies and Infrastructure**
- ✓ **Value Addition to our Clients**
- ✓ **Our Team**
- ✓ **Glimpse into our Facility**
- ✓ **To Summarize**



ABOUT PARAS BIOPHARMACEUTICALS




Your Partner of choice for Microbial Manufacturing

- Finnish Company located in Oulu, Finland
- Established 2013
- Setup by a group of scientists and technologists who have extensive experience, skills and a successful track record in developing biologics
- Microbial technology-focused company with interests in CDMO services & Bioprocess Enzymes



Your Domain Antibody CDMO



CDMO services and Bioprocess Enzymes

CDMO Services

- ✓ Cell-line Development
- ✓ Upstream and Downstream Process Development
- ✓ Analytical Methods Development and Qualification
- ✓ Technology Transfer
- ✓ Scale up
- ✓ Large-Scale Manufacturing
- ✓ Stability Studies



Bioprocess Enzymes

- ✓ Recombinant TEV Protease (RAPID TEV®)
- ✓ Recombinant Enterokinase (EK)
- ✓ Other custom-made



Capabilities, Knowledge and Experience



Microbial CDMO with strong customer focus

50+ batches in the last few years on different molecules



Experience in working with:


- ***E. coli***
- ***S. cerevisiae***
- ***P. pastoris***
- ***B. subtilis*** and other microbial strains



Innovative, cost-saving services with maximum efficiency and Speed



Quality at different scales



DOE Approach with AKTA Avant

MICROBIAL TECHNOLOGIES AND INFRASTRUCTURE



Paras Proprietary Microbial Technologies

DIABRID® TECHNOLOGY

Optimized protocols and procedures are used along with economical method to facilitate highly efficient refolding of proteins.

NOBLECLEAV® TECHNOLOGY


Incorporates gene construct with Paras Proprietary Partner and Spacers, enabling high expression yields for difficult and challenging proteins

BIOMULTIFOLD® TECHNOLOGY

Enables achievement of multigram of proteins per liter of fermentation

CYTOFOLD STRUCTQUANT® TECHNOLOGY

Expression of recombinant proteins / peptides in the cytoplasm of an *E. coli* as fully active proteins



Major USP & DSP Equipment

Upstream

- 2 x 10L, 2 X 20L, 1 X 150L and 1 X 750L scales SS bioreactors (B. Braun/Sartorius)
- Homogenizers, Centrifuges (continuous and batch)



Downstream


- Chromatographic separations (IEX, affinity, HIC, SEC, RP-HPLC)
- 2 Tangential Flow Filtration Units (Sartorius), from 0.1 to 6 m²
- 3 AKTA Systems (Avant, Explorer 10, 100) & 16 Axichrom columns – Axichrom 50, Axichrom 140, Axichrom 30P and Chromatographic units (GE-Healthcare)
- Protein crystallizer (Custom made)
- Lyophilization unit (Telstar)
- Decontamination and sterilization autoclaves
- Chromatographic separation: ion exchange, affinity, hydrophobic interaction, SEC, RP-HPLC
- Filtration: microfiltration, ultrafiltration, diafiltration, membrane adsorption

Analytical Laboratory and Instrumentation

- High Pressure Liquid Chromatography (Agilent 1260/1290)
- Gas Chromatograph – Mass Spectrometer (Agilent 9000, 5977B)
- LCMS QTOF (Agilent1260/6530)
- Capillary Electrophoresis (Hewlett Packard 3D CE)
- Toledo titrators DL53 and DL38 (KF); Mettler Toledo refractometer RE40D
- FT-IR Spectrometer (PerkinElmer Spectrum One)
- SDS-Polarimeter (Jasco P-1020); TOC Analyzer (Shimadzu TOC-5000A)
- UV / Vis Spectrophotometer (Shimadzu UV-2401 PC)
- Microplate / ELISA Reader (Labsystems iEMS Reader MF)
- Melting point apparatus (Buchi B-545); SDS-PAGE, Scales, pH-meters, TLC
- Chromeleon (Version 7.0) – connected data analysis and reporting



Analytical Capabilities and Documentation



Production Facility Overview

- Total floor area 25,000 ft²
- Classified cleanroom 4,300 ft²
- Media and buffer preparation
- Live area (fermentation and harvest & extraction)
- Purification suite (three separate rooms, including +4°C cold room)
- Final filtration and freeze-drying
- Facility in Operation since 2003
- Fully equipped with modern analytical lab facilities and utilities, HVAC system and SCADA controls
- Team comprises a group of experienced scientists, technologists and process engineers



Production Facility Overview

- Utilities to cleanroom through panels, piping mainly in technical fingers
- As little piping inside the cleanroom as possible
- Unknown processes => design based on series of concept processes
- Features of containment level BL3
- Production area in A/B, C and D classes
- Operator rooms in key areas with electronic card access
- Workshop and stores
- Facility upgradation ongoing for new Quality Systems Management (QMS)
- Successful track record in offering innovative, cost-saving *E. coli* / microbial technologies




VALUE ADDITION TO OUR CLIENTS



Feasibility Studies

- Paras Biopharma believes in creating win-win opportunities
- Paras Biopharma is a client-focused company
- Feasibility studies: share risks and rewards
- Carry out initial feasibility studies to check the expression of your proteins by our technologies
- Modestly priced
- 3-5 months on an average to ship few mg of proteins for testing



Technology Transfer – Support Systems

- Understanding customer technology
- Designing Process for Technology Transfer
- Custom solutions
- Cost efficient solutions
- Timeline based approach
- Regular updates
- State of the art facility



Project Management – With Our Clients, Always



Customer-Focused Culture



- ✓ Expertise – providing solutions
- ✓ Partnership philosophy
- ✓ Flexible and scalable capacity aligned to customer needs
- ✓ 100% commitment to every project – small or big
- ✓ Professionalism, transparency and ease of doing business with us


Our Clients in the USA & European Union

A few examples of our clientele include:


- A large (multibillion dollar) business conglomerate in the USA
- One of the top 10 global pharmaceutical companies from Europe
- Small Biopharma companies in Europe and the USA

**“It has been great working with your team on our projects” VP,
CMC of a US biopharma company**

**“ We have been impressed working with ParasBio & are confident
that the *project name – confidential* run will be successful” CEO
of a European pharmaceutical Company.**




Creating Excellence in Biologics Dev. & Production



Our Team



Business Leadership



**Dr Hans
Söderlund**

**Director - Global Strategic
Alliance**


- Responsible for global alliance & strategic growth



**Dr Ashesh
Kumar**

**CEO & Director – Biologics
& Licensing**

- Responsible for Paras' biologics development program



**Dr John
Coates**

**Mentor – Business
Collaborations**

- International collaboration and future business prospecting



**Dr Mark
Jackson**

**Company
Administration
Lead**



**Martti
Särkelä**

Business Advisor


Company Advisory Board



Prof. Dr Taina
Pihlajaniemi

Advisory Board

- Professor of molecular medicine and vice rector research, University of Oulu, Finland



Dr Hans
Söderlund

**Chairman – Advisory
Board**

- Chairman of Board of Director at the University of Oulu and Chairman of SAB



Mr Anil Sharma

Advisory Board

- Director & investor for several international companies with diverse business segments.



Prof. Dr Heikki
Ojamo

Advisory Board

- Professor of Protein Science & Biochemistry at Aalto University, Finland



A Glimpse Into Our Facility





Fermentation / Bioreactors
2x10L, 2x15L, 150L, 750L

PARTEC BIOPHARMACEUTICALS

CONFIDENTIAL



150L with MSDS controls

PA BIOPHARMACEUTICALS

CONFIDENTIAL



Commercial Full-Scale Chromatography Columns

PARAS BIOPHARMACEUTICALS

CONFIDENTIAL



***Large scale HPLC & Commercial
Novasep 150 column***

AS BIOPHARMACEUTICALS

CONFIDENTIAL

A scientist in a white lab coat is working in a laboratory. The scene is filled with complex machinery, including a large stainless steel column in the foreground and various pipes and tubes in the background. The lighting is bright, and the overall atmosphere is professional and technical.

***Ätkä Pilot & large Axichrom columns
for development & production***

PARAS BIOPHARMACEUTICALS

CONFIDENTIAL



Scale-up HPLC and kromasil columns

PARAS BIOPHARMACEUTICALS

CONFIDENTIAL



Lyophilization

A photograph of a modern production facility. The building features a large, arched entrance on the left and a large, rectangular structure in the center covered in white protective sheeting. A tall, slender tree stands in the foreground, partially obscuring the building. To the right, a modern building with a dark, perforated facade is visible. A blue banner is overlaid at the bottom of the image.

***Production Facility & Upcoming
Building Expansions***

To Summarize

- Paras Biopharma is your partner of choice for microbial Manufacturing.
- We are a microbial technology-focused company with interests in CDMO services & Bioprocess Enzymes.
- We have experience in working with: ***E. coli***, ***S. cerevisiae***, ***P. pastoris***, ***B. subtilis*** and other microbial strains.
- We provide microbial CDMO services from scratch to batch and have state-of-art infrastructure for development and production of recombinant biologics.
- We have a strong project management team in place to look into client needs and our focus is always keeping our clients at the centre.
- Our clientele includes large and small companies spread across the USA, EU and other regions.
- We have an experienced team always ready to take up challenging projects and helping our clients in their product development endeavours.

Paras Biopharma Vision, Mission & Value Creation

Our Vision


"Quality and Improved Healthcare for all by Providing Specialized Skills and Technology Platforms" for Enhanced Biologics production.

Our Mission


To “strive to create” biologic solutions through manufacturing innovations and bioprocessing tools for producing & enabling difficult-to-produce Biologics.

Our Value Creation

Our Collaborative approach and freedom to operate in full trust and confidentiality allows us to deliver an unparalleled approach to introduce new and innovative technologies for our clients.



Key Biologics CDMO Industry Drivers in 2021 and Beyond





ADDRESS

Paras Biopharmaceuticals Finland Oy, Kiviharjunlenkki 10, Oulu, 90220, Finland

Phone: Mobile: +358 44 270 9462

E-MAIL

bd@parasbiopharma.com

info@parasbiopharma.com

SOCIAL

parasbiopharma.com

twitter.com/parasbiopharm



Confidentiality & Disclaimer

This presentation, including information contained in this disclaimer, is given to you in strict confidence. By receiving the presentation, you agree that no part of this presentation or disclaimer may be disclosed, distributed or reproduced to any third party without the consent of Paras Biopharmaceuticals Finland Oy (also known as Paras Biopharma & Paras).

This presentation is made available for the sole purpose of providing the recipients with background information about Paras Biopharmaceuticals Finland Oy's business and bio-business in general. This presentation, including the information contained in this disclaimer, does not constitute an offer, invitation or recommendation to subscribe for or purchase any security and neither the presentation, disclaimer nor anything contained within them forms the basis of any contract or commitment.

The presentation contains information that is general and any numbers related to sales figures of molecules or brands are presented for the purpose of reference and may not be the correct numbers nor may be similar to other assessments in the industry. These are Paras' own assessments and therefore the company is not liable for their correctness, not liable if these numbers are inaccurate and are same as assessed by others. This presentation does not purport to summarize all information that a company or an investor should consider when making a decision.

This presentation may contain information which is general or generic in nature and the company holds no responsibility for this. The information may be part of general information available on the webpages or through website search. It should be read in conjunction with Paras Biopharma's other documents or emails. Before making any assessment or decision you should consider whether it is suitable for you in light of your profile and objectives and financial circumstances and the merits and risk involved.

The molecules and information discussed in the presentation, as well as technology from Paras Biopharmaceuticals Finland Oy is restricted and the work on molecules that are patented are only research projects. These molecules or API will not be offered for any commercial use. The purpose of the presentation is not for commercial sale and so it does include academic and non- commercial data.